Full text
PDFPage 955
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Falkson G., van Dyk J. J., van Eden E. B., van der Merwe A. M., van den Bergh J. A., Falkson H. C. A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213. Cancer. 1975 Apr;35(4):1141–1144. doi: 10.1002/1097-0142(197504)35:4<1141::aid-cncr2820350418>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
- Kovach J. S., Moertel C. G., Schutt A. J., Reitemeier R. G., Hahn R. G. Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep. 1973 Sep-Oct;57(3):357–359. [PubMed] [Google Scholar]
- Loike J. D., Horwitz S. B. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry. 1976 Dec 14;15(25):5435–5443. doi: 10.1021/bi00670a003. [DOI] [PubMed] [Google Scholar]
- Ostrow S., Hahn D., Wiernik P. H., Richards R. D. Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep. 1978 Oct;62(10):1591–1594. [PubMed] [Google Scholar]
- Wiltshaw E., Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed] [Google Scholar]